A woman who lost over two stone in just four months has revealed how she was able to quit weight-loss jabs for good by 'micro ...

Novo Nordisk saw sales growth for its diabetes and obesity care segment slow in the first half of 2025, confirming investor ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The number of people taking weight-loss injections is exploding. With more and more men going “on the needle”, here’s what ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat distribution, with greater weight loss linked to better outcomes, a study ...